EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy

Zhuomiao Lin, Meiqing Yang, Xihui Yu, Guozhu Tan, Jiahong Zhong

Frontiers in Pharmacology · 07.01.2025 · 15

DOI: 10.3389/fphar.2024.1505768 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.01.2025. Verfasst von Zhuomiao Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Meizhou People's Hospital (Huangtang Hospital), Meizhou, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Non-alcoholic steatohepatitis (NASH) is a progressive liver disease with lipid accumulation, inflammation, and liver fibrosis. Ponatinib, a third-generation tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, was found to improve metabolic disorders in mice. However, the role of ponatinib in liver inflammation and fibrosis remains to be elucidated. Here we aimed to determine the effect of ponatinib in non-alcoholic steatohepatitis.

Methods

We explored the function and mechanism of ponatinib using a mouse model of NASH induced by a methionine and choline deficient (MCD) diet and LO2 cells cultured in MCD mimic medium.

Results

Here, we found that ponatinib reduced liver lipid deposition, fibrosis, and inflammation induced by MCD diet without affecting body weight and blood glucose. Meanwhile, we found that ponatinib attenuated steatohepatitis and inflammation in LO2 cells induced by MCD mimic medium. We further discovered that the expression levels of LC3II and lysosomal associated membrane protein 1 (LAMP1) were reduced and the expression level of p62 was upregulated in both mouse and cell models, suggesting that autophagy was inhibited, which was restored by ponatinib treatment. In addition, transcription factor EB (TFEB) is a major regulator of autophagy and lysosome biogenesis and the transcription and protein expression levels of TFEB were decreased in steatosis hepatocytes, which could be ameliorated by ponatinib treatment.

Conclusion

These results revealed that the beneficial effects of ponatinib on NASH via TFEB-mediated autophagy.

Schlagwörter

Stichwörter der Autor:innen

NASHTFEBautophagymethionine and choline deficient dietponatinib

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Meizhou People's Hospital (Huangtang Hospital), Meizhou, China.
  • Joint Shantou International Eye Center, Shantou University and The Chinese University of Hong Kong, Shantou, China.
  • Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
  • Department of Orthopaedics and Traumatology, The Seventh Affiliated Hospital, Southern Medical University, Foshan, China.

Zitieren

APA

Lin, Z., Yang, M., Yu, X., Tan, G., & Zhong, J. (2025). Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1505768

Vancouver

Lin Z, Yang M, Yu X, Tan G, Zhong J. Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy. Frontiers in Pharmacology. 2025;15. doi:10.3389/fphar.2024.1505768

BibTeX
@article{Lin2025,
  author = {Lin, Zhuomiao and Yang, Meiqing and Yu, Xihui and Tan, Guozhu and Zhong, Jiahong},
  title = {Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fphar.2024.1505768}
}
Kostenlos starten →